Literature DB >> 21397441

In-hospital and 30-day outcomes after tibioperoneal interventions in the US Medicare population with critical limb ischemia.

Todd R Vogel1, Viktor Y Dombrovskiy, Jeffrey L Carson, Alan M Graham.   

Abstract

OBJECTIVES: Catheter-based revascularization has emerged as an alternative to surgical bypass for the tibioperoneal vessels. The purpose of this analysis was to describe the outcomes of tibial angioplasty interventions for critical limb ischemia (CLI) in the hospitalized Medicare population, to examine in-hospital complications, to define the 30-day readmission and mortality rates, and to assess secondary procedures performed in this population.
METHODS: In-patients with CLI undergoing tibioperoneal angioplasty were identified using The Centers for Medicare & Medicaid Services in-patient claims for 2005 to 2007. In-hospital complications, mortality, 30-day secondary procedures, and 30-day rehospitalization after discharge were described.
RESULTS: A total of 13,258 in-patients underwent tibioperoneal angioplasty (54.2% men; 75.7% white, 17.1% African American; 42.8% gangrene, 46.7% rest pain, 10.5% claudication) and 29.3% had a stent, 47.3% had femoral-popliteal angioplasty, and 20.1% had atherectomy during their initial procedure. Initial hospital complications included renal complications (8.1%), respiratory complications and pneumonia (5.1%), and cardiac complications with acute myocardial infarction (3.2%). Mortality in-hospital was 2.8% and at 30 days was 6.7%. Thirty-day rehospitalization rate was 29.6%. Thirty-day reinterventions included repeat angiogram (8.5%), repeat tibioperoneal angioplasty (3.2%), open bypass (2.1%), and lower extremity amputations (23.8%). Gangrene was the most frequent diagnosis at rehospitalization (13.5%). Patients with gangrene as an indication for tibioperoneal angioplasty were 1.8 times (95% confidence interval [CI], 1.56-2.10) as likely as patients with rest pain to be rehospitalized during 30 days after discharge. Among comorbidities, predictors of 30-day rehospitalization included chronic renal failure (odds ratio [OR], 1.4; 95% CI, 1.27-1.52), chronic pulmonary disease (OR, 1.1; 95% CI, 1.01-1.25), and congestive heart failure (CHF; OR, 1.1; 95% CI, 1.01-1.22). About one-quarter of patients (23.8%) within 30 days after their initial procedure underwent amputation at any level of the lower limb.
CONCLUSION: Tibioperoneal angioplasty is associated with frequent in-hospital complications, an overall 30-day amputation rate of 23.8% for all procedures and indications, and a 30-day rehospitalization rate of almost 30%. Further detailed analysis of tibioperoneal intervention is essential to define best treatment strategies and to minimize complications and readmission rates.
Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397441     DOI: 10.1016/j.jvs.2010.12.055

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  12 in total

1.  Risk factors and indications for readmission after lower extremity amputation in the American College of Surgeons National Surgical Quality Improvement Program.

Authors:  Thomas Curran; Jennifer Q Zhang; Ruby C Lo; Margriet Fokkema; John C McCallum; Dominique B Buck; Jeremy Darling; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2014-06-28       Impact factor: 4.268

2.  Risk factors for 30-day unplanned readmission following infrainguinal endovascular interventions.

Authors:  Thomas C F Bodewes; Peter A Soden; Klaas H J Ultee; Sara L Zettervall; Alexander B Pothof; Sarah E Deery; Frans L Moll; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-02       Impact factor: 4.268

3.  Risk Factors for 30-Day Hospital Re-Admission with an Infectious Complication after Lower-Extremity Vascular Procedures.

Authors:  Joseph C Melvin; Jamie B Smith; Robin L Kruse; Todd R Vogel
Journal:  Surg Infect (Larchmt)       Date:  2017-02-08       Impact factor: 2.150

4.  Two-year clinical outcomes following lower limb endovascular revascularisation for chronic limb-threatening ischaemia at a tertiary Asian vascular centre in Singapore.

Authors:  Wei Ling Tay; Tze Tec Chong; Sze Ling Chan; Hao Yun Yap; Kiang Hiong Tay; Marcus Eng Hock Ong; Edward Tieng Chek Choke; Tjun Yip Tang
Journal:  Singapore Med J       Date:  2020-07-16       Impact factor: 3.331

5.  The association of postoperative glycemic control and lower extremity procedure outcomes.

Authors:  Todd R Vogel; Jamie B Smith; Robin L Kruse
Journal:  J Vasc Surg       Date:  2017-04-19       Impact factor: 4.268

6.  Outcomes following infrapopliteal angioplasty for critical limb ischemia.

Authors:  Ruby C Lo; Jeremy Darling; Rodney P Bensley; Kristina A Giles; Suzanne E Dahlberg; Allen D Hamdan; Mark Wyers; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2013-02-01       Impact factor: 4.268

7.  Risk factors for readmission after lower extremity bypass in the American College of Surgeons National Surgery Quality Improvement Program.

Authors:  Jennifer Q Zhang; Thomas Curran; John C McCallum; Li Wang; Mark C Wyers; Allen D Hamdan; Raul J Guzman; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2014-01-31       Impact factor: 4.268

8.  Complex relationship between low albumin level and poor outcome after lower extremity procedures for peripheral artery disease.

Authors:  Jonathan Bath; Jamie B Smith; Jennifer Woodard; Robin L Kruse; Todd R Vogel
Journal:  J Vasc Surg       Date:  2020-05-26       Impact factor: 4.268

9.  Growing impact of restenosis on the surgical treatment of peripheral arterial disease.

Authors:  Douglas W Jones; Andres Schanzer; Yuanyuan Zhao; Todd A MacKenzie; Brian W Nolan; Michael S Conte; Philip P Goodney
Journal:  J Am Heart Assoc       Date:  2013-11-25       Impact factor: 5.501

10.  Hospital Readmissions Following Endovascular Therapy for Critical Limb Ischemia: Associations With Wound Healing, Major Adverse Limb Events, and Mortality.

Authors:  Grant W Reed; Pejman Raeisi-Giglou; Rami Kafa; Umair Malik; Negar Salehi; Mehdi H Shishehbor
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.